SCHEMBL25407409

SCHEMBL25407409

CC(C)CC(=O)NC[C@H](N)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.48
GFPT1 Q06210 1/20 0.46
SLC1A3 P43003 3/20 0.42
SLC1A2 P43004 3/20 0.42
PSMB5 P28074 1/20 0.41
GRIK1 P39086 3/20 0.41
SLC1A1 P43005 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 2/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
GRIA2 P42262 2/20 0.39
GRIA4 P48058 2/20 0.39
GRIK3 Q13003 2/20 0.39
GRIK5 Q16478 2/20 0.39
GRIA1 P42261 1/20 0.39
GRIK2 Q13002 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8231097 1.00 SLC7A5 (0.48) SLC7A5GFPT1SLC1A3SLC1A2PSMB5
SCHEMBL1768507 0.88 GFPT1 (0.46) SLC7A5GFPT1SLC1A3SLC1A2GRIK1
SCHEMBL28095721 0.88 GFPT1 (0.46) SLC7A5GFPT1SLC1A3SLC1A2GRIK1
SCHEMBL25410006 0.86 GFPT1 (0.45) SLC7A5GFPT1SLC1A3SLC1A2GRIK1
SCHEMBL25410008 0.86 GFPT1 (0.45) SLC7A5GFPT1SLC1A3SLC1A2GRIK1
SCHEMBL5082612 0.84 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2GRIK1SLC1A1
SCHEMBL5082599 0.84 SLC7A5 (0.54) SLC7A5SLC1A3SLC1A2GRIK1SLC1A1
SCHEMBL1768908 0.79 GFPT1 (0.49) SLC7A5GFPT1SLC1A3SLC1A2GRIK1
SCHEMBL1768905 0.79 GFPT1 (0.49) SLC7A5GFPT1SLC1A3SLC1A2GRIK1
SCHEMBL27761217 0.79 CYP2D6 (0.43) PSMB5CYP2D6CYP2C19TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170216-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-05-29 US disclosed
US-20230295259-A1 Conjugated Hepcidin Mimetics PROTAGONIST THERAPEUTICS, INC. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295259-A1 Conjugated Hepcidin Mimetics HAMP, VIP, HDGF SLC7A5 927/4885GFPT1 1286/4885SLC1A3 2450/4885
US-20250170216-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF SLC7A5 930/4885GFPT1 1484/4885SLC1A3 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.